Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12626743 | 0.89 | CDK1 (0.47) | SIGMAR1SIRT1USP2TP53TSHR | |
| SCHEMBL1992105 | 0.88 | MCHR1 (0.47) | SIGMAR1SIRT1BAZ2BMCHR1 | |
| SCHEMBL155100 | 0.81 | MCHR1 (0.44) | SIGMAR1TSHRCYP1A2CYP2D6MCHR1 | |
| SCHEMBL1988850 | 0.80 | SIGMAR1 (0.67) | SIGMAR1 | |
| SCHEMBL156880 | 0.77 | MCHR1 (0.46) | SIGMAR1MCHR1 | |
| SCHEMBL22000226 | 0.77 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL2810909 | 0.73 | SIGMAR1 (0.60) | SIGMAR1 | |
| SCHEMBL23828240 | 0.72 | CFTR (0.41) | SIGMAR1MCHR1 | |
| SCHEMBL31020946 | 0.72 | CFTR (0.41) | SIGMAR1MCHR1 | |
| SCHEMBL2815558 | 0.69 | SIGMAR1 (0.64) | SIGMAR1USP2TSHRCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778959-B2 | AZA-bridged ring-fused indoles and indolines | ABBVIE INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110152306-A1 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152306-A1 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES | INMT, IDO1, IDO2 | SIGMAR1 2033/4885SIRT1 589/4885USP2 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.